Professional Marketing briefs

Share this article:
Shire CEO Angus Russell, seeking to stem concerns about an OIG investigation of his firm's ADHD sales and marketing practices, said such inquiries have “almost become standard practice” in this industry and that “at this stage, it's a general inquiry.” Shire revealed that it had been subpoenaed for information on Adderall XR, Daytrana and Vyvanse promotion.

Eli Lilly is trimming its osteoporosis, diabetes and neurosciences sales forces by a total of 191 jobs as part of a restructuring plan announced in September, Indianapolis Business Journal reports. The company intends to lay off 5,500 by 2011 in an effort to soften the blow when Zyprexa, which has $4.7 billion in global sales, goes off patent the same year.

Warner Chilcott completed its $3.1 billion acquisition of P&G's global branded prescription pharmaceuticals unit, securing a 1,200-person sales force and a portfolio worth $2.3 billion in annual revenue. The company, based in Ireland, now markets such former P&G products as blockbuster brand Actonel (risedronate) for osteoporosis and colitis drug Asacol (mesalamine).


Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters